sorafenib has been researched along with apatinib in 8 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (apatinib) | Trials (apatinib) | Recent Studies (post-2010) (apatinib) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 575 | 109 | 544 |
Protein | Taxonomy | sorafenib (IC50) | apatinib (IC50) |
---|---|---|---|
Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.001 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (37.50) | 24.3611 |
2020's | 5 (62.50) | 2.80 |
Authors | Studies |
---|---|
Duo, J; Ma, X; Zhao, Y; Zhu, H | 1 |
Han, Z; He, Z; Wang, C; Wang, Q | 1 |
Du, Y; Kong, L; Liang, Q; Tian, J; Zhu, X | 1 |
Hu, Y; Wu, L; Ye, Z; Zhang, X; Zheng, L | 1 |
Cao, Y; Chen, L; Kan, X; Liang, B; Ouyang, T; Xiong, F; Zheng, C | 1 |
Dai, JY; Jiang, B; Liu, KC; Lu, D; Lv, WF; Tan, YL; Wang, GX; Yin, L; Zhu, XH | 1 |
Bai, Y; Chan, SL; Chen, C; Chen, Y; Chen, Z; Cheng, AL; Cheng, Y; Gu, S; Guo, Y; Hu, X; Jia, W; Jin, Y; Kaseb, A; Li, W; Liang, J; Liang, X; Lin, X; Melisi, D; Meng, Z; Osypchuk, Y; Pazgan-Simon, M; Pisetska, M; Ponomarenko, D; Qin, S; Ren, H; Ren, Z; Sinielnikov, I; Sultanbaev, A; Vogel, A; Wang, L; Xiong, J; Yang, F; Yang, TS; Zeng, Y | 1 |
Chen, D; Chen, X; Kang, M; Wang, Y; Zhu, L | 1 |
1 trial(s) available for sorafenib and apatinib
Article | Year |
---|---|
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib | 2023 |
7 other study(ies) available for sorafenib and apatinib
Article | Year |
---|---|
The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report.
Topics: Adult; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Fatal Outcome; Humans; Liver Neoplasms; Lung; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed | 2018 |
The effect of apatinib in the treatment of sorafenib resistant metastatic hepatocellular carcinoma: A case report.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Neoplasm; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Pyridines; Sorafenib | 2018 |
Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Imaging; Molecular Targeted Therapy; Multimorbidity; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2019 |
Quantification of sorafenib, lenvatinib, and apatinib in human plasma for therapeutic drug monitoring by UPLC-MS/MS.
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Drug Monitoring; Humans; Liver Neoplasms; Pharmaceutical Preparations; Phenylurea Compounds; Pyridines; Quinolines; Reproducibility of Results; Sorafenib; Tandem Mass Spectrometry | 2021 |
Efficacy of apatinib in patients with sorafenib-transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2021 |
Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Propensity Score; Retrospective Studies; Sorafenib | 2023 |
Assessing the effectiveness of camrelizumab plus apatinib versus sorafenib for the treatment of primary liver cancer: a single-center retrospective study.
Topics: Body Weight; Humans; Liver Neoplasms; Retrospective Studies; Sorafenib | 2023 |